321.85
+0.83%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Penumbra
From its filings with the US Securities and Exchange Commission
Penumbra is based in Alameda, California and is incorporated in Delaware. Its shares trade on NYSE under the ticker PEN. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $1.40bn and net income of $177.7m. At that date it held total assets of $1.83bn and shareholders' equity of $1.43bn. By business, Thrombectomy brought in 67.5% of revenue, followed by Embolization and Other at 32.5%. By region, United States accounted for 77.8%, followed by International at 22.2%.
Penumbra, the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety, and simplicity. Our team focuses on developing, manufacturing and marketing novel products for use by specialist physicians and other healthcare providers to drive improved clinical and health outcomes. We believe that the cost-effectiveness of our products is attractive to our customers.
Since our founding in 2004, we have invested heavily in our product development and commercial expansion that has established the foundation of our global organization. We have successfully developed, obtained regulatory clearance or approval for, and introduced products into the thrombectomy market since 2007, access market since 2008, embolization market since 2011, and neurosurgical market since 2014.
We expect to continue to develop and build our portfolio of products, including our thrombectomy, embolization, and access technologies, while iterating on our currently available products. Generally, when we introduce a next generation product or a new product designed to replace a current product, sales of the earlier generation product or the product replaced decline.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 18 Sept 2015
- Employees
- 4,700
- Website
- penumbrainc.com ↗
- Head office
- ONE PENUMBRA PLACE, ALAMEDA, CA, 94502
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Adam ElsesserChairman of the Board, Chief Executive Officer, since 2004$630,467
- Ms. Shruthi NarayanPresident
- Ms. Maggie YuenChief Financial Officer$1.8m
- Ms. Johanna RobertsExecutive Vice President, General Counsel, Secretary$2.2m
- Mr. Lambert ShiuChief Accounting Officer$1.6m
- Mr. Thomas WilderPresiding Independent Director$258,922
- Dr. Arani BoseDirector, since 2005$233,922
- Mr. Harpreet GrewalIndependent Director$241,422
- Ms. Janet LeedsIndependent Director$251,422
- Ms. Bridget O'RourkeIndependent Director$263,922
- Ms. Surbhi SarnaIndependent Director$248,922
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 60
- Environment
- 46
- Social
- 72
- Governance
- 63
- Women in the workforce
- 50%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Penumbra Inc has several strengths that contribute to its success in the market. These include:
Weaknesses
- Despite its strengths, Penumbra Inc also faces certain weaknesses that may hinder its growth prospects. These include:
Opportunities
- Penumbra Inc can leverage various opportunities to expand its market share and increase profitability. These opportunities include:
Threats
- Penumbra Inc faces various threats that could impact its growth and profitability. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.